The article contains short characteristics of 6 novel European guidelines on the treatment of cardiovascular diseases and accounts of main scientific sessions (Hot Line, Clinical Trial and Registry Update) of the European Society of Cardiology Congress 2012.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Best evidence summary for nutritional management of cancer patients with chyle leaks following surgery.
Front Nutr
January 2025
Department of Urinary Surgery, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Background: Chyle leaks (CL) is a significant postoperative complication following lymph node dissection in cancer patients. Persistent CK is related to a series of adverse outcomes. Nutritional management is considered an effectively strategy that treat CL.
View Article and Find Full Text PDFSudoscan reclassifies cardiovascular risk in patients with type 2 diabetes mellitus according to the ESC 2023.
J Diabetes Metab Disord
June 2025
Research Department, Hospital Clinica Nova de Monterrey, Av. Del Bosque 139 Cuahtemoc, San Nicolas de los Garza, Nuevo León, 66450 México.
Objectives: The objective of this study is to determine if the detection of DAN through Sudoscan can reclassify cardiovascular risk in patients with T2DM according to the European Society of Cardiology guidelines 2023 (ESC 2023) compared to other risk scales.
Methods: A retrospective cross-sectional analytical study was conducted on 161 patients with T2DM who had undergone Sudoscan in a Northern Mexico Hospital between December 2022 and July 2023. We compared the cardiovascular risk with SCORE-2, SMART, ADVANCE, ASCVD plus, and Globo Risk scales.
Tofersen and other antisense oligonucleotides in ALS.
Ther Adv Neurol Disord
January 2025
Department of Neurology, Ulm University, Ulm, Germany.
The advent of antisense oligonucleotide (ASO) therapies in neurodegenerative disorders is associated with enormous hope. Nusinersen treatment was a breakthrough intervention in the recessive disease spinal muscular atrophy, and superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) seems to be the paradigm disease in dominant degenerative diseases. The results of treatment with the ASO tofersen in SOD1-ALS show that the drug has a convincing beneficial effect on ALS caused by SOD1 mutations, that preclinical studies in rodents predicted the therapeutic effect in the human disease, and that clinical efficacy is associated with a specific sequence of effects of the drug on mechanistic and degenerative biomarkers and, subsequently, functional outcomes such as weight stabilization and ALSFRS-R.
View Article and Find Full Text PDFLiving with pulmonary arterial hypertension: a patient's perspective on dyspnoea crises.
Breathe (Sheff)
January 2025
European Lung Foundation, Sheffield, UK.
https://bit.ly/4gxgIBC.
View Article and Find Full Text PDFPD-L1 expression in PitNETs: Correlations with the 2022 WHO classification.
Brain Spine
December 2024
Division of Neurosurgery, Department of Clinical Neurosciences, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Introduction: and research question: Prognostic factors to predict the behavior of pituitary neuroendocrine tumors (PitNET) are scarce. PD-L1 expression was associated with prognosis in other neuroendocrine neoplasms and we analyzed PD-L1 expression in PitNET, according to the 2022 WHO classification.
Material And Methods: A retrospective analysis was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!